gadolinium-chelate
Phase 2Small molecule
gadolinium-chelate is one of 133 small molecule programs targeting Metastasis. It is currently in Phase 2.
4
Indications
5
Total Trials
2
Active Trials
132
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1gadolinium-chelate
MM.D. Anderson Cancer Center
Phase 2
Blenoxane
Bristol-Myers SquibbPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastasis1 trial
Breast Cancer1 trial
Glioblastoma, IDH-wildtype1 trial
Pancreatic Ductal Adenocarcinoma1 trial
DCE-MRI-Informed Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
Not yet recruiting·OOhio State University Comprehensive Cancer Center·Preclinical·NCT07705919·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for gadolinium-chelate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MM.D. Anderson Cancer Center